Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06124963
- Locations
- 🇨🇳
The Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital), Shanghai, Shanghai, China
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06117566
- Locations
- 🇨🇳
the first affiliated hospital of Jilin university, Changchun, Jilin, China
Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 32
- Registration Number
- NCT06114940
- Locations
- 🇨🇳
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing, Jiangsu, China
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Registration Number
- NCT06105008
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳Binghe Xu, Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
🇨🇳Hunan Cancer Hospital, Changsha, China
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 20
- Registration Number
- NCT06093438
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT06088004
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, China
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 33
- Registration Number
- NCT06081582
- Locations
- 🇨🇳
Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Target Recruit Count
- 108
- Registration Number
- NCT06080854
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06079112
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06078982
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.